ESR1 and prostate carcinoma: Given that ERβ release from epigenetic silencing elicits beneficial antiandrogenic effects in prostate cancer models, the subtype-selective ER ligands of both natural and synthetic origin may have a significant role in novel preventive and curative strategies for this oncopathology [150,151].